KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Settembre 2024 - 12:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted nine newly-hired employees inducement options to purchase
an aggregate of 55,000 shares of KalVista common stock on September
3, 2024 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $12.37 per share, which
was equal to the closing price of KalVista common stock on the
grant date. One-fourth of the options vest on the one-year
anniversary of the vesting commencement date and the remainder vest
in equal monthly installments over the next three years, in each
case subject to the new employee’s continued service with the
company. Each stock option has a 10-year term and is subject to the
terms and conditions of KalVista’s Inducement Equity Incentive Plan
and a stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc. KalVista
Pharmaceuticals, Inc. is a global pharmaceutical company focused on
the development and delivery of oral medicines for diseases with
significant unmet need. KalVista announced positive phase 3 data
from the KONFIDENT trial for its oral, on-demand therapy,
sebetralstat for HAE in February 2024. The Company’s NDA for
sebetralstat has been accepted by the FDA with a PDUFA goal date of
June 17, 2025. In addition, KalVista received validation of its MAA
from the EMA in August 2024. KalVista expects to file for approval
in the UK, Japan, and other countries later in 2024.
For more information about KalVista, please visit
www.kalvista.com or follow on social media at @KalVista and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904377554/en/
KalVista Pharmaceuticals, Inc. Media: Jenn Snyder
Vice President, Corporate Affairs (857) 356-0479
jennifer.snyder@kalvista.com
Investors: Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Dic 2023 a Dic 2024
